Hemostatic Disorders 
Welcome,         Profile    Billing    Logout  

16 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hemostatic Disorders
FAST, NCT02611973: Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia

Recruiting
3
2250
Europe
Aspirin therapy interruption, Usual treatment by aspirin 100 mg/d in the active comparator arm, No interruption of aspirin in the Observational arm, Hydroxyurea treatment (HU)
Assistance Publique - Hôpitaux de Paris
MPN, Essential Thrombocythemia
11/19
11/22
Myeloma XI, NCT01554852 / 2009-010956-93: Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients

Checkmark From P3 Myeloma XI trial in NDDM at ASH 2016
Dec 2016 - Dec 2016: From P3 Myeloma XI trial in NDDM at ASH 2016
Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Active, not recruiting
3
4420
Europe
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Revlimid (lenalidomide), Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen, Kyprolis (carfilzomib), Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen, Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen, Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen, Velcade (bortezomib), Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance, Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance, Zolinza (vorinostat), High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)
University of Leeds, Celgene, Merck Sharp & Dohme LLC, Amgen
Multiple Myeloma
12/21
12/22
NCT01754402: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Active, not recruiting
1/2
56
US
Bendamustine, Treanda, Bendeka, Pomalidomide, CC-4047, Pomalyst, Dexamethasone
Cristina Gasparetto, Celgene
Multiple Myeloma
12/16
01/25
TMI-ASCT, NCT00800059: Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

Recruiting
1/2
27
Canada
Total Marrow Irradiation, TMI
Ottawa Hospital Research Institute
Multiple Myeloma
11/20
11/25
NCT01250808: Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy

Available
N/A
RoW
Bortezomib/Dexamethasone/Melphalan
Peking University
Multiple Myeloma
 
 
NCT01701947: HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency

No Longer Available
N/A
US
Hemoleven, Human Coagulation Factor XI
Laboratoire français de Fractionnement et de Biotechnologies
Wound; Rupture, Surgery, Cesarean Section, Postpartum Hemorrhage, Surgery
 
 
NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

No Longer Available
N/A
US
Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
01/15
01/15
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.

No Longer Available
N/A
US
Plerixafor, AMD3100, Mozobil
Genzyme, a Sanofi Company
Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
 
 
NCT00999414: UARK 2009-32 Compassionate Use Study of Carfilzomib

No Longer Available
N/A
US
Carfilzomib
University of Arkansas, Onyx Therapeutics, Inc.
Multiple Myeloma
04/15
04/15
NCT02541643: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

No Longer Available
N/A
US
Elotuzumab, BMS-901608
Sundar Jagannath, Bristol-Myers Squibb
Multiple Myeloma
 
 
NCT00799539: A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

No Longer Available
N/A
Canada
bortezomib, melphalan, prednisone
Janssen-Ortho Inc., Canada, Ortho Biotech Canada
Multiple Myeloma
 
 
NCT02204553: Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

No Longer Available
N/A
US
Panobinostat
Novartis Pharmaceuticals
Multiple Myeloma
 
 
NCT02666209: Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

No Longer Available
N/A
US
Ulocuplumab, BMS-936564, Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Decadron
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Multiple Myeloma in Relapse, Multiple Myeloma
 
 
NCT02751554: PET Imaging of Patients Using 124I-PU-AD

Recruiting
N/A
10
US
124I-PU-AD, PET Scan, Blood draws
Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Rockefeller University, Samus Therapeutics, Inc.
Solid Malignancy, Lymphoma, Multiple Myeloma, Alzheimer's Disease
04/18
08/18
CoMMpass, NCT01454297: Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

Completed
N/A
1154
Europe, Canada, US
Multiple Myeloma Research Foundation, Translational Genomics Research Institute, Spectrum Health Hospitals, Van Andel Research Institute
Multiple Myeloma
11/23
12/23
NCT02869555: Institut Paoli Calmettes Multiple Myeloma Database

Recruiting
N/A
5000
Europe
Data collection
Institut Paoli-Calmettes
Multiple Myeloma
01/30
12/30

Download Options